Table 1.

Review of literature of long‐term survivor mCRC patient treated with regorafenib

Patient's characteristics	Pretretments	Regorafenib‐OS	Months of regorafenib treatment	References
Caucasian male, 67 y	Cetuximab plus irinotecan‐based bevacizumab plus oxaliplatin and 5‐FU Rechallenge with panitumumab rechallenge of an oxaliplatin‐based CT	13 mo	13 mo	Rosati7
Caucasian male, 59 y	Folfox‐Bevacizumab Folfiri‐Bevacizumab Folfox‐Cetuximab	24 mo	17 mo	Callebout8
Asiatic male, 54 y	FOLFIRI Oral FU plus LV XELOX‐bevacizumab FOLFIRI‐panitumumab mFOLFOX6‐panitumumabmab	24 mo+	24 mo+	Yoshino9
Caucasian male, 54 y	FOLFOX‐4 FOLFIRI‐aflibercept	36 mo (interspersed by RT)	36 mo+	Roberto10
Caucasian male, 54 y	FOLFOX‐4 FOLFIRI‐aflibercept	30 mo (interspersed by RT)	25 mo	Korphaisarn11
Caucasian male, 63 y	FOLFOX Folfiri‐Bevacizumab	25 mo	25 mo	Amram22
Caucasian female, 57 y	Xelox Folfiri‐Bevacizumab	25 mo	25 mo	Present report

Abbreviations: CT, chemotherapy; FU, fluorouracil; LV, leucovorin; OS, overall survival; RT, radiotherapy; ys, years.